高原红细胞增多症（HAPC）已成为严重威胁高原人群健康的主要常见慢性疾病之一。在藏医药经典古籍《四部医典》中记载有该病的治疗方法及药物，具有疗效明确、副作用小等独特优势。本文对藏医药防治HAPC的病因病机、临床治疗优势和现代创新研究做了分析，并针对目前藏医药治疗HAPC临床有效性规范化不足、藏药复方的药效物质基础与作用机制不清楚等问题，提出在继承藏医药理论基础上，以临床疗效为根本，将藏医药原创思维与现代科技结合，加强藏医药治疗HAPC古籍文献整理与用药经验数据挖掘，规范临床治疗标准和用药方案，以代谢组学等系统生物学现代研究手段，进一步研究藏医药治疗HAPC的科学内涵。

High altitude polycythemia (HAPC) had become one of the main common chronic diseases, which had seriously threatened the health of Plateau people. In the Tibetan medicine classic book Si-Bu Yi-Dian, there were recordings on HAPC treatment methods and medications, which had the unique advantages of identified therapeutic effect with little side effect. This article analyzed Tibetan medicine in the prevention and treatment of HAPC from aspects such as etiology and pathogenesis, clinical treatment advantages and modern innovation study. Questions were also raised on lacking of standardization on HAPC clinical effectiveness, as well as Tibetan medicine compound material basis and action mechanisms were unclear. It was proposed that based on the inheritance of Tibetan medicine theoretical basis and clinical therapeutic effect, the Tibetan medicine original thinking should be combined with modern science and technology, in order to strengthen the analysis of ancient literature collection in HAPC treatment and data mining in medication experiences. The clinical treatment standards and medication plan should be standardized. Methods of systems biology, such as metabolomics, can be used in the further study of the scientific connotation of HAPC treatment by Tibetan medicine.

科学技术部国家“973”课题（2012CB518200-G）：高原低氧环境的快速习服与长期适应机制研究，负责人：张艺；国家自然科学基金委面上项目（30900715）：HAPC藏医多血症的生物学基础及藏药三果汤散干预研究，负责人：张艺；国家自然科学基金委面上项目（30750006）：藏药多血康对高原多血症红细胞及EPO、HIF 基因表达的影响，负责人：索朗其美；国家自然科学基金委面上项目（30960507）：中藏药治疗高原红细胞增多症的多靶点筛选评估系统研究，负责人：旺堆；国家自然科学基金委面上项目（81203000）：藏药红景天“预适应”对缺氧脑损伤神经保护及其线粒体MPTP机制探讨，负责人：张静；国家自然科学基金委面上项目（81403187）：基于脑保护的藏药蔓菁抗高原缺氧药效物质基础与作用机制研究，负责人：邝婷婷；教育部博士点基金博导类课题（20095132110008）：藏药三果汤散防治高原红细胞增多症药效物质基础的代谢组学研究，负责人：张艺；江西中医药大学2011协同创新开放基金项目：藏药复方红景天胶囊防治高原肺动脉高压的新药成药性研究，负责人：王毓杰。